Mathai Mammen - 14 Feb 2022 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Role
EVP, Pharm, R&D
Signature
Raavi Deol, as attorney-in-fact for Mathai Mammen
Issuer symbol
JNJ
Transactions as of
14 Feb 2022
Net transactions value
-$394,265
Form type
4
Filing time
15 Feb 2022, 19:03:54 UTC
Previous filing
13 Jan 2022
Next filing
17 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $0 +7,418 +23% $0.000000 39,895 14 Feb 2022 Direct F1
transaction JNJ Common Stock Tax liability $394,265 -2,335 -5.9% $168.85 37,560 14 Feb 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Restricted Share Units Options Exercise $0 -7,418 -100% $0.000000* 0 14 Feb 2022 Common Stock 7,418 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Share Units awarded under Issuer's Long-Term Incentive Plan on February 11, 2019; converted into shares of Common Stock upon vesting.
F2 Shares withheld for payment of taxes upon vesting of Restricted Share Units.